zirabev

Generic: bevacizumab-bvzr

Labeler: pfizer laboratories div pfizer inc
NDC Directory HUMAN PRESCRIPTION DRUG BLA Inactive Finished

Drug Facts

Product Profile

Brand Name zirabev
Generic Name bevacizumab-bvzr
Labeler pfizer laboratories div pfizer inc
Dosage Form INJECTION, SOLUTION
Routes
INTRAVENOUS
Active Ingredients

bevacizumab 400 mg/16mL

Manufacturer
Pfizer Laboratories Div Pfizer Inc

Identifiers & Regulatory

Product NDC 0069-0342
Product ID 0069-0342_3135aec5-1b5d-4de4-9b73-bfeb7821b75d
Product Type HUMAN PRESCRIPTION DRUG
Marketing Category BLA
Application Number BLA761099
Listing Expiration 2026-12-31
Marketing Start 2020-01-13

Pharmacologic Class

Established (EPC)
vascular endothelial growth factor inhibitor [epc]
Mechanism of Action
vascular endothelial growth factor-directed antibody interactions [moa] vascular endothelial growth factor inhibitors [moa]

Normalized Code Variants

Searchable formats for this product NDC code

Digits Only 00690342
Hyphenated Format 0069-0342

Supplemental Identifiers

RxCUI
2268039 2268044 2268047 2268048
UPC
0300690342016
UNII
2S9ZZM9Q9V
NUI
N0000193543 N0000178291 N0000193542

Packaging Origin

Original Packager
true

Resolved Product View

Precedence rule: structured NDC data is preferred, falling back to linked label metadata when unavailable. Source tags show the origin of each value.

Resolved Identity

Brand Name zirabev (source: ndc)
Generic Name bevacizumab-bvzr (source: ndc)
Application Number BLA761099 (source: ndc)
Routes
INTRAVENOUS
source: ndc

Resolved Composition

Strengths
  • 400 mg/16mL
source: ndc
Packaging
  • 1 VIAL, SINGLE-USE in 1 CARTON (0069-0342-01) / 16 mL in 1 VIAL, SINGLE-USE
source: ndc

Packages (1)

0069-0342-01 1 VIAL, SINGLE-USE in 1 CARTON (0069-0342-01) / 16 mL in 1 VIAL, SINGLE-USE

Ingredients (1)

bevacizumab (400 mg/16mL)

Linked Drug Pages (1)

Zirabev ndc-match (0.9)

Raw FDA Data

View complete raw FDA NDC JSON payload 
{"route": ["INTRAVENOUS"], "spl_id": "3135aec5-1b5d-4de4-9b73-bfeb7821b75d", "openfda": {"nui": ["N0000193543", "N0000178291", "N0000193542"], "upc": ["0300690342016"], "unii": ["2S9ZZM9Q9V"], "rxcui": ["2268039", "2268044", "2268047", "2268048"], "spl_set_id": ["aa27acbd-d117-4350-aeee-17bc2e2c0ca4"], "pharm_class_epc": ["Vascular Endothelial Growth Factor Inhibitor [EPC]"], "pharm_class_moa": ["Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]", "Vascular Endothelial Growth Factor Inhibitors [MoA]"], "manufacturer_name": ["Pfizer Laboratories Div Pfizer Inc"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "1 VIAL, SINGLE-USE in 1 CARTON (0069-0342-01)  / 16 mL in 1 VIAL, SINGLE-USE", "package_ndc": "0069-0342-01", "marketing_start_date": "20200113"}], "brand_name": "Zirabev", "product_id": "0069-0342_3135aec5-1b5d-4de4-9b73-bfeb7821b75d", "dosage_form": "INJECTION, SOLUTION", "pharm_class": ["Vascular Endothelial Growth Factor Inhibitor [EPC]", "Vascular Endothelial Growth Factor Inhibitors [MoA]", "Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]"], "product_ndc": "0069-0342", "generic_name": "bevacizumab-bvzr", "labeler_name": "Pfizer Laboratories Div Pfizer Inc", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Zirabev", "active_ingredients": [{"name": "BEVACIZUMAB", "strength": "400 mg/16mL"}], "application_number": "BLA761099", "marketing_category": "BLA", "marketing_start_date": "20200113", "listing_expiration_date": "20261231"}